AU Patent

AU2019282253A1 — Inhibitors of integrated stress response pathway

Assigned to Altos Labs Inc · Expires 2020-11-26 · 5y expired

What this patent protects

The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.

USPTO Abstract

The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019282253A1
Jurisdiction
AU
Classification
—
Expires
2020-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Altos Labs Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.